HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

NCT05263453 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: HL-085
DRUG: Vemurafenib

Sponsor

Shanghai Kechow Pharma, Inc.